Overview
Erythromycin ethylsuccinate is an esterified derivative of erythromycin, developed to improve oral bioavailability. As a macrolide antibiotic, it inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. The ethylsuccinate modification enhances stability in gastric acid, making it suitable for oral administration. This compound is particularly effective against Gram-positive bacteria and some Gram-negative organisms. It is commonly prescribed for pediatric formulations due to its palatability and reliable absorption profile.
Physical and Chemical Properties
The compound presents as a white to slightly yellow crystalline powder with characteristic faint odor. Its solubility profile favors organic solvents like ethanol (freely soluble) over water (slightly soluble), which influences formulation development. Thermal analysis shows stability up to 135°C, beyond which decomposition occurs. The ester bond is susceptible to hydrolysis under strongly acidic or alkaline conditions, requiring pH-controlled environments during pharmaceutical manufacturing.
Main Applications
Primarily used in oral antibiotic preparations, erythromycin ethylsuccinate treats respiratory tract infections (pharyngitis, tonsillitis), skin/soft tissue infections, and pertussis. Its pediatric suspensions account for approximately 30% of macrolide prescriptions for children in some markets. In veterinary medicine, it's employed for similar indications in livestock. Recent research explores potential anti-inflammatory effects unrelated to its antimicrobial properties, though clinical applications remain investigational.
Safety and Storage
Standard storage requires protection from light and moisture at controlled room temperature (15-25°C). Degradation products from improper storage may reduce efficacy and increase adverse effects. Occupational handling necessitates PPE including gloves and dust masks, particularly during bulk processing. The material safety data sheet classifies it as causing serious eye irritation (Category 2A under GHS). Spills should be contained with inert absorbents.
B2B Procurement Guide
Bulk pharmaceutical buyers should prioritize suppliers with: 1) Current Good Manufacturing Practice (cGMP) certification, 2) Batch-specific Certificate of Analysis including HPLC purity ≥98%, 3) Residual solvent testing (meets ICH Q3C guidelines). Packaging typically uses double polyethylene bags within fiber drums (25kg net) or custom quantities. Spot prices fluctuate with erythromycin raw material costs. Long-term contracts (6-12 months) often secure 10-15% discounts versus spot purchases.